Watchlist Price Alert

Immunome Inc. (IMNM)

NASDAQ: IMNM · Real-Time Price · USD

8.01

0.10 (1.26%)

At close: May 13, 2025, 3:59 PM

1.26% (1D)

Bid	8.01
Market Cap	696.97M
Revenue (ttm)	9.04M
Net Income (ttm)	-292.96M
EPS (ttm)	-5
PE Ratio (ttm)	-1.6
Forward PE	-2.76
Analyst	Buy

Ask	8.08
Volume	36,209
Avg. Volume (20D)	1,123,466
Open	7.91
Previous Close	7.91
Day's Range	7.91 - 8.06
52-Week Range	5.15 - 16.81
Beta	2.01

About IMNM

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol IMNM

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for IMNM stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Immunome has released their quartely earnings on May 12, 2025:

Revenue of $2.93M exceeds estimates by $2.47M, with 184.35% YoY growth.

EPS of -0.52 exceeds estimates by 0.05, with 79.28% YoY growth.

Why Price Moved

1 month ago

+7.19%

Immunome shares are trading higher after Lake Stre... Unlock content with Pro Subscription

3 months ago

+1.19%

Immunome shares are trading lower after the company announced a $125 million proposed public offering.

News

1 day ago · zacks.com

All You Need to Know About Immunome (IMNM) Rating Upgrade to Buy

Immunome (IMNM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 day ago · zacks.com

Immunome, Inc. (IMNM) Reports Q1 Loss, Tops Revenue Estimates

Immunome, Inc. (IMNM) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to loss of $0.34 per share a year ago.

6 days ago · zacks.com

Wall Street Analysts Believe Immunome (IMNM) Could Rally 249.93%: Here's is How to Trade

The consensus price target hints at a 249.9% upside potential for Immunome (IMNM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimat...

1 week ago · businesswire.com

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced toda...

3 weeks ago · seekingalpha.com

Immunome: Transformed Pipeline Offers Multiple Catalysts

Immunome's unique human immune memory-based discovery engine and strategic pipeline expansion in oncology present a compelling investment opportunity, especially post-merger with Morphimmune. The comp...

1 month ago · businesswire.com

Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome ...

1 month ago · zacks.com

Immunome, Inc. (IMNM) Reports Q4 Loss, Misses Revenue Estimates

Immunome, Inc. (IMNM) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to loss of $0.54 per share a year ago.

1 month ago · businesswire.com

Immunome Reports Full Year 2024 Financial Results and Provides Business Update

2 months ago · businesswire.com

Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC